Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a bupivacaine liposome injectable suspension, administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Parsippany, New Jersey.
IPO Year: 2011
Exchange: NASDAQ
Website: pacira.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/13/2024 | $30.00 → $8.00 | Buy → Sell | Truist |
| 8/12/2024 | $42.00 → $11.00 | Overweight → Neutral | Piper Sandler |
| 8/12/2024 | $45.00 → $10.00 | Overweight → Underweight | JP Morgan |
| 8/12/2024 | Outperform → Mkt Perform | Raymond James | |
| 8/12/2024 | $37.00 → $14.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 7/3/2024 | $38.00 → $25.00 | Overweight → Equal Weight | Barclays |
| 3/7/2024 | $80.00 → $45.00 | Overweight | JP Morgan |
| 12/20/2023 | $42.00 | Outperform | Raymond James |
| 8/3/2023 | $50.00 | Market Perform → Outperform | TD Cowen |
| 1/31/2023 | $88.00 → $60.00 | Outperform | Wedbush |
10-Q - Pacira BioSciences, Inc. (0001396814) (Filer)
8-K - Pacira BioSciences, Inc. (0001396814) (Filer)
8-K - Pacira BioSciences, Inc. (0001396814) (Filer)
8-K - Pacira BioSciences, Inc. (0001396814) (Filer)
8-K - Pacira BioSciences, Inc. (0001396814) (Filer)
8-K - Pacira BioSciences, Inc. (0001396814) (Filer)
10-Q - Pacira BioSciences, Inc. (0001396814) (Filer)
8-K - Pacira BioSciences, Inc. (0001396814) (Filer)
8-K - Pacira BioSciences, Inc. (0001396814) (Filer)
144 - Pacira BioSciences, Inc. (0001396814) (Subject)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
3 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4/A - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4/A - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
Pacira BioSciences (NASDAQ:PCRX) has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 2 1 0 0 Last 30D 1 0 0 0 0 1M Ago 2 1 1 0 0 2M Ago 0 0 0 0 0 3M Ago 2 1 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $41.88, with a high estimate of $57.00 and a low estimate of $25.00. Highlighting a 8.72% decrea
Truist Securities analyst Les Sulewski maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and lowers the price target from $45 to $30.
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro. Here's the latest list of major oversold players in this sector, having an RSI near or below 30. Cassava Sciences Inc (NASDAQ:SAVA) On July 1, Cassava Sciences engaged the U.S. Department of Justice (DOJ) and the U.S. Secu
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. DA Davidson analyst Kurt Yinger downgraded the rating for AZEK Co (NYSE:AZEK) from Buy to Neutral, while lowering the price target from $57 to $44. AZEK shares gained 0.8% to close at $41.63 on Tuesday. See how other analysts view this stock. Barclays analyst David Strauss downgraded Spirit AeroSystems Holdings, Inc. (NYSE:SPR) from Overweight to Equal-Weight and slashed the price target from $40 to $37. Spirit AeroSystems shares fell 0.3% to trade at $33.88 on Tuesday. See how other a
Piper Sandler analyst David Amsellem maintains Pacira BioSciences (NASDAQ:PCRX) with a Overweight and maintains $42 price target.
Barclays analyst Balaji Prasad downgrades Pacira BioSciences (NASDAQ:PCRX) from Overweight to Equal-Weight and lowers the price target from $38 to $25.
https://www.accessdata.fda.gov//scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214348
Analysts' ratings for Pacira BioSciences (NASDAQ:PCRX) over the last quarter vary from bullish to bearish, as provided by 6 analysts. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 1 0 0 0 Last 30D 2 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 2 1 0 0 0 3M Ago 1 0 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $47.17, along with a high estimate of $57.00 and a low estimate of $38.00. Experiencing a 2.54% decline, the curren
Truist downgraded Pacira BioSciences from Buy to Sell and set a new price target of $8.00 from $30.00 previously
Piper Sandler downgraded Pacira BioSciences from Overweight to Neutral and set a new price target of $11.00 from $42.00 previously
JP Morgan downgraded Pacira BioSciences from Overweight to Underweight and set a new price target of $10.00 from $45.00 previously
Raymond James downgraded Pacira BioSciences from Outperform to Mkt Perform
RBC Capital Mkts downgraded Pacira BioSciences from Outperform to Sector Perform and set a new price target of $14.00 from $37.00 previously
Barclays downgraded Pacira BioSciences from Overweight to Equal Weight and set a new price target of $25.00 from $38.00 previously
JP Morgan resumed coverage of Pacira BioSciences with a rating of Overweight and set a new price target of $45.00 from $80.00 previously
Raymond James initiated coverage of Pacira BioSciences with a rating of Outperform and set a new price target of $42.00
TD Cowen upgraded Pacira BioSciences from Market Perform to Outperform and set a new price target of $50.00
Wedbush resumed coverage of Pacira BioSciences with a rating of Outperform and set a new price target of $60.00 from $88.00 previously
PARSIPPANY, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced new data demonstrating its gene therapy for osteoarthritis candidate, PCRX-201 (enekinragene inzadenovec), provided sustained improvements in knee pain, stiffness, and function to 104 weeks following local administration, with a well-tolerated safety profile. The data, which indicate a potential for sustained clinical efficacy in patients with moderate to severe osteoarthritis of the knee (OAK), will be presented during a poster session at the American College of Rheumatol
PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences: Jefferies London Healthcare Conference on Tuesday, November 19th at 3:00PM GMT (10:00AM ET).36th Annual Piper Sandler Healthcare Conference on Tuesday, December 3rd at 1:00PM ET. Live audio of the events can be accessed by visiting the "Events" page of the company's website at investor.pacira.com. A replay of the webcasts will also be available for two weeks following the events. About PaciraPacira BioSciences delivers innovative, non-opioid pain therapies to transform
-- Conference call today at 4:30 p.m. ET -- PARSIPPANY, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today reported financial results for the third quarter of 2024. Third Quarter 2024 Financial Highlights Total revenues of $168.6 millionNet product sales of $132.0 million for EXPAREL, $28.4 million for ZILRETTA, and $5.7 million for iovera°Net loss of $143.5 million, or $3.11 per share (basic and diluted)Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $54.7 million See "Non-GAAP Financial Information" below. "2024 continues to be highligh
-- Final CMS rule concludes iovera is a qualifying device for separate payment under the NOPAIN Act -- -- Beginning January 1, 2025, providers can receive additional Medicare payment when they use EXPAREL or iovera° via product-specific reimbursement codes -- PARSIPPANY, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NSDQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced that the Centers for Medicare and Medicaid Services (CMS) issued its final Medicare Hospital Outpatient Prospective Payment System (OPPS) and Medicare Ambulatory Surgical Center (ASC) Payment System rule for 2025
PARSIPPANY, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results after the close of the U.S. markets on Wednesday November 6, 2024. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the "Events" page on the Paci
TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the appointment of Shawn Cross as Chief Financial Officer. In this role, Mr. Cross will be responsible for overseeing all aspects of the company's financial operations. "We are delighted to welcome Shawn as our new Chief Financial Officer and look forward to his leadership and guidance as we invest in long-term growth and value creation while maintaining high standards in resource allocation and execution," said Frank D. Lee, chief executive officer of Pacira BioSciences. "Shawn brings a strong set of experienc
TAMPA, Fla., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on October 2, 2024 to 55 new employees under Pacira's Amended and Restated 2014 Inducement Plan as a material inducement to each employee's entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the Compensation Committee of the Board of Directors. 10 employees received stock options to purchase an aggregate of 68,900 shares of Pacira common stock and 54 employees received restricted stock units for an aggregate of
-- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement -- TAMPA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced that the Centers for Medicare and Medicaid Services (CMS) has established a permanent product-specific Healthcare Common Procedure Coding System (HCPCS) J-code for EXPAREL® (bupivacaine liposome injectable suspension). The new J-code for EXPAREL, J0666, becomes effective January 1, 2025, and will supersede the current C-code (C9290), which has been in place since 2019.
-- Poster to be presented at ACR Convergence annual meeting -- TAMPA, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the upcoming presentation of new data in support of its gene therapy candidate, PCRX-201 (enekinragene inzadenovec). The data will be presented at the American College of Rheumatology's annual ACR Convergence meeting, being held in Washington, D.C. November 14–19. Presentation Title: Sustained Clinical Effects After a Single Intra-articular Injection of PCRX-201 for Moderate-to-Severe Osteoarthritis of the Knee Presented By: Stanley Cohen, MD, a
Believes Pacira's Cash Balance of $400 million, Roughly 59% of its Market Capitalization, is Grossly Inefficient. Emphasizes the Current Stock Price Offers an Extraordinary Opportunity to Create Meaningful Return for Shareholders MIAMI, Sept. 25, 2024 /PRNewswire/ -- DOMA Perpetual Capital Management LLC today sent a letter to the Board of Directors of Pacira Biosciences (NYSE: PCRX) urging the Board to accelerate and increase its stock repurchase. The letter can be downloaded here The full text of the letter follows: September 24, 2024 To the Board Members of Pacira Bioscien
enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of
-- Transformational Leader Brings Three Decades of Global Experience in Pharmaceutical and Biotechnology Product Development and Commercialization -- -- Paul J. Hastings Named Chair of the Board -- -- Dave Stack to Remain in Advisory Role through August 2025 -- TAMPA, Fla., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that its Board of Directors (the "Board") has appointed Frank D. Lee as Chief Executive Officer and a member of the Board, effective January 2, 2024. As previously announced in September 2023, David Stack will retire from his r
-- Enhances diversity and expertise in key areas including scientific, commercial, and financial -- TAMPA, Fla., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the appointments of Marcelo Bigal, MD, PhD, Abraham Ceesay, Michael Yang, and Alethia Young, to its Board of Directors effective immediately. "We are pleased to welcome these four highly seasoned executives to our Board of Directors, whose experience will enhance our board as we advance on our strategic objectives across multiple key areas," said Dave Stack, chairman and chief executive
David Stack to Retire as Chairman and CEO Once Successor is Appointed Board Has Initiated Search for Successor TAMPA, Fla., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that David ("Dave") Stack will retire from his role as Chairman and Chief Executive Officer. To ensure a seamless transition, Mr. Stack has committed to continuing in his current role until a new CEO is appointed by the board of directors, who are conducting the search. He will then continue in a consulting role with the company through August of 2025. "On behalf of our enti
TAMPA, Fla., April 19, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the appointment of Christopher Young to the position of Chief Manufacturing Officer. Mr. Young will be responsible for oversight of all manufacturing activities across the Pacira product portfolio including supply chain design, product life cycle management, demand and requirements planning, capacity, and product launches across all global manufacturing locations. "Chris is a seasoned operations professional with strong and well-rounded manufacturing expertise, and a keen leadership ac
Mr. Scibetta is an accomplished biotech executive who brings over 20 years of experience successfully leading life science companies from early-stage platform development through major value-generating milestones ImmuneID, Inc., a precision immunology company employing a proprietary platform to identify and therapeutically target antibody interactions that drive immune diseases, today announced the appointment of James S. Scibetta as Chief Executive Officer and a member of the Board of Directors. Mr. Scibetta succeeds David Donabedian, Ph.D., Venture Partner of Longwood Fund, who had been serving as CEO and will serve in an advisory capacity to the Company. This press release features mult
SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)
SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)
SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)
SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)
SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)
SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)
SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)
SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)
SC 13G - Pacira BioSciences, Inc. (0001396814) (Subject)
SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)
-- Conference call today at 4:30 p.m. ET -- PARSIPPANY, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today reported financial results for the third quarter of 2024. Third Quarter 2024 Financial Highlights Total revenues of $168.6 millionNet product sales of $132.0 million for EXPAREL, $28.4 million for ZILRETTA, and $5.7 million for iovera°Net loss of $143.5 million, or $3.11 per share (basic and diluted)Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $54.7 million See "Non-GAAP Financial Information" below. "2024 continues to be highligh
PARSIPPANY, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results after the close of the U.S. markets on Wednesday November 6, 2024. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the "Events" page on the Paci
-- Conference call today at 4:30 p.m. ET -- TAMPA, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the second quarter of 2024. Second Quarter 2024 Financial Highlights Total revenues of $178.0 millionNet product sales of $136.9 million for EXPAREL, $30.7 million for ZILRETTA, and $5.7 million for iovera°Net income of $18.9 million, or $0.41 per share (basic) and $0.39 per share (diluted)Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $62.1 million See "Non-GAAP Financial Informatio
TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results after the close of the U.S. markets on Tuesday July 30, 2024. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the "Events" page on the Pacira websit
-- Conference call today at 4:30 p.m. ET -- TAMPA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the first quarter of 2024. First Quarter 2024 Financial Highlights Total revenues of $167.1 millionNet product sales of $132.4 million for EXPAREL, $25.8 million for ZILRETTA, and $5.0 million for iovera°Net income of $9.0 million, or $0.19 per share (basic and diluted)Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $44.6 million See "Non-GAAP Financial Information" below. "Sales are
TAMPA, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results after the close of the U.S. markets on Tuesday May 7, 2024. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. To participate in the conference call, dial 1-800-715-9871 and provide the passcode 6363041. International callers may dial 1-646-307-1963 and use the same passcode. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the "Events" page on the Pacira website at investor.pacira.com. About Pacira Pacira
— Record revenues of $675 million in 2023 — — Full-year GAAP net income of $42 million and adjusted EBITDA of $214 million — — EXPAREL surpasses the 14 million patient mark — — Conference call today at 8:30 a.m. ET — TAMPA, Fla., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the fourth quarter and full-year of 2023. "Now that I have spent several weeks working with the Pacira team, I am even more enthusiastic to lead this great company as we build upon an impressive foundation of success," said Frank D. Lee, chief exec
TAMPA, Fla., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2023 financial results before the open of the U.S. markets on Thursday February 29, 2024. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through
-- New ASA initiatives to advance education and innovation for the anesthesia community -- -- PDUFA action date for EXPAREL as a lower extremity nerve block on track for November 13, 2023 -- -- Conference call today at 8:30 a.m. ET -- TAMPA, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the third quarter of 2023. Third Quarter 2023 Financial Highlights Total revenues of $163.9 millionNet product sales of $128.7 million for EXPAREL, $28.8 million for ZILRETTA, and $5.3 million for iovera°Net income of $10.9 millio
TAMPA, Fla., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on Thursday November 2, 2023. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the "Events" page on the Pacira web